Results 11 to 20 of about 105,726 (291)

Effect of Tacrolimus vs Intravenous Cyclophosphamide on Complete or Partial Response in Patients With Lupus Nephritis

JAMA Network Open, 2022
Key Points Question What is the efficacy and safety of tacrolimus vs intravenous cyclophosphamide (IVCY) as initial therapy for lupus nephritis (LN) among Chinese patients?
Zhaohui Zheng, Haitao Zhang, Xiao-mei Peng, Chun Zhang, C. Xing, Gang Xu, P. Fu, Z. Ni, Jianghua Chen, Zhonggao Xu, Ming-hui Zhao, Shaomei Li, Xiangyang Huang, Lining Miao, Xiao-nong Chen, Bicheng Liu, Yongcheng He, Jing Li, Lijun Liu, Haishan Kadeerbai, Zhangsuo Liu, Zhihong Liu   +21 more
semanticscholar   +1 more source

Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case Report

Transplantation Proceedings, 2022
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has had a significant impact on communities and health systems. New antiviral medications against this disease have not been properly tested yet, and their efficiency, side ...
M. Prikis, A. Cameron
semanticscholar   +1 more source

Insights into the Pharmacogenetics of Tacrolimus Pharmacokinetics and Pharmacodynamics

Pharmaceutics, 2022
The influence of pharmacogenetics in tacrolimus pharmacokinetics and pharmacodynamics needs further investigation, considering its potential in assisting clinicians to predict the optimal starting dosage and the need for a personalized adjustment of the ...
M. Brunet, M. Pastor-Anglada
semanticscholar   +1 more source

The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.

Kidney International, 2020
A cyclical corticosteroid-cyclophosphamide regimen is recommended for patients with primary membranous nephropathy at high risk of progression. We hypothesized that sequential therapy with tacrolimus and rituximab is superior to cyclical alternating ...
G. Fernández-Juárez, J. Rojas-Rivera, A. V. D. Logt, Joana Justino, Á. Sevillano, F. Caravaca-Fontán, A. Ávila, C. Rabasco, V. Cabello, A. Varela, M. Díez, G. Martín-Reyes, Marian Goicoechea Diezhandino, L. Quintana, I. Agraz, J. Gomez-martino, M. Cao, A. Rodríguez-Moreno, B. Rivas, C. Galeano, J. Bonet, A. Romera, A. Shabaka, E. Plaisier, M. Espinosa, J. Egido, A. Segarra, G. Lambeau, P. Ronco, J. Wetzels, M. Praga   +30 more
semanticscholar   +1 more source

Avoiding Tacrolimus Underexposure and Overexposure with a Dosing Algorithm for Renal Transplant Recipients: A Single Arm Prospective Intervention Trial

Clinical pharmacology and therapy, 2021
Bodyweight‐based tacrolimus dosing followed by therapeutic drug monitoring is standard clinical care after renal transplantation. However, after transplantation, a meager 38% of patients are on target at first steady‐state and it can take up to 3 weeks ...
M. Francke, L. Andrews, Hoang Lan Le, J. van de Wetering, M. C. Clahsen‐van Groningen, T. van Gelder, R. V. van Schaik, B. van der Holt, B. D. de Winter, D. Hesselink   +9 more
semanticscholar   +1 more source

3D printed tacrolimus suppositories for the treatment of ulcerative colitis

Asian Journal of Pharmaceutical Sciences, 2020
Ulcerative colitis is a global health problem, affecting millions of individuals worldwide. As an inflammatory condition localised in the large intestine, rectal delivery of immunosuppressive therapies such as tacrolimus is a promising strategy to ...
Iria Seoane-Viaño, J. J. Ong, A. Luzardo-Álvarez, M. González-Barcia, A. Basit, F. Otero-Espinar, A. Goyanes   +6 more
semanticscholar   +1 more source

Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report

Therapeutic Drug Monitoring, 2019
: Ten years ago, a consensus report on the optimization of tacrolimus was published in this journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicity (IATDMCT)
M. Brunet, T. van Gelder, A. Åsberg, V. Haufroid, D. Hesselink, L. Langman, F. Lemaître, P. Marquet, C. Seger, M. Shipkova, A. Vinks, P. Wallemacq, E. Wieland, J. Woillard, M. Barten, K. Budde, H. Colom, M. Dieterlen, L. Elens, K. Johnson-Davis, P. Kunicki, I. Macphee, S. Masuda, B. Mathew, O. Millán, T. Mizuno, D. Moes, C. Monchaud, Ofelia Noceti, T. Pawiński, N. Picard, R. V. van Schaik, C. Sommerer, N. T. Vethe, B. D. de Winter, U. Christians, S. Bergan   +36 more
semanticscholar   +1 more source

Population Pharmacokinetic Models of Tacrolimus in Adult Transplant Recipients: A Systematic Review

Clinical Pharmacokinetics, 2020
Numerous population pharmacokinetic (PK) models of tacrolimus in adult transplant recipients have been published to characterize tacrolimus PK and facilitate dose individualization.
R. Kirubakaran, S. Stocker, S. Hennig, R. Day, J. Carland   +4 more
semanticscholar   +1 more source

No Evidence of Increased Cancer Incidence in Children Using Topical Tacrolimus for Atopic Dermatitis.

Journal of American Academy of Dermatology, 2020
BACKGROUND Long-term safety of topical calcineurin inhibitors is not well understood. APPLES™ (A Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis (AD); NCT00475605)
A. Paller, R. Fölster-Holst, Suephy C. Chen, T. Diepgen, C. Elmets, D. Margolis, Brad H. Pollock   +6 more
semanticscholar   +1 more source

Butyric acid normalizes hyperglycemia caused by the tacrolimus‐induced gut microbiota

American Journal of Transplantation, 2020
Approximately 33.6% of nondiabetic solid organ transplant recipients who received tacrolimus developed hyperglycemia. Whether the tacrolimus‐induced gut microbiota is involved in the regulation of hyperglycemia has not been reported.
W. Jiao, Zijian Zhang, Yue Xu, Lian Gong, Weixun Zhang, Hao Tang, S. Zeng, Qiang Zhang, Zhaoli Sun, Ling Liu, Xiaopeng Hu   +10 more
semanticscholar   +1 more source